Malignant melanoma is the most invasive and deadly form of skin cancer with no effective therapy to treat advanced disease, leading to poor survival rates. Targeted combinatorial therapeutics is needed that inhibit proteins or pathways causing melanoma. Regrettably, relatively few targets have been identified or no therapeutic agents are available to inhibit them. Recently, we identified elevated Akt3 activity occurring in ~70% of sporadic melanomas compared to normal cells. Functionally, active Akt3 reduces responsiveness of melanomas to agents that would normally kill via apoptosis, thereby promoting tumorigenesis and development of chemoresistance. Unfortunately, no agents are available to inhibit this important pathway in melanomas. Furthermore, it is unknown whether targeting Akt3 signaling would be therapeutically sufficient or whether a combinatorial approach targeting other melanoma causing proteins, such as V600E B-Raf, would be necessary for an effective therapeutic. Based on these important unanswered questions, the central hypothesis for this proposal is that targeting Akt3 signaling alone or in combination with V600E B-Raf inhibition would be an effective targeted approach for inhibiting melanoma. The hypothesis will be tested by: (1) characterizing the utility of novel synthetic isothiocyanate and isoselenocyanate derivatives that inhibit Akt3 signaling to reduce melanoma tumorigenesis and metastasis;and (2) determining the therapeutic potential of a combinatorial approach targeting Akt3 and V600E B-Raf signaling in melanomas. We are prepared to undertake the proposed research, having demonstrated that the Akt3 and V600EB-Raf pathways are key therapeutic targets in melanoma and development of novel synthetic compounds derived from chemopreventive isothiocyanates to inhibit Akt3 signaling. Accomplishing these goals would be highly significant, providing novel insight into the therapeutic implications of targeting a major signaling pathway in melanoma, and provide solid rationale for initiating clinical trials in melanoma patients targeting Akt3 signaling. For melanoma patients, these discoveries could ultimately lead to development of improved therapeutics that would increase length and quality of life for individuals suffering from this disease. Over the long-term, discovery of therapeutics and effective approaches to inhibit the Akt3 signaling pathway are predicted to have a significantly positive impact on the currently poor prognosis faced by advanced-stage melanoma patients. Specifically these agents would contribute to the availability of more effective therapies, which would increase the length and quality of life for melanoma patients. Therefore, the positive impact of this study on the melanoma therapeutics field will be significant.

Public Health Relevance

Over the long-term, discovery of therapeutics and effective approaches to inhibit the Akt3 signaling pathway are predicted to have a significantly positive impact on the currently poor prognosis faced by advanced-stage melanoma patients. Specifically these agents would contribute to the availability of more effective therapies, which would increase the length and quality of life for melanoma patients. Therefore, the positive impact of this study on the melanoma therapeutics field will be significant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA127892-03
Application #
7742174
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Arya, Suresh
Project Start
2007-12-17
Project End
2012-11-30
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
3
Fiscal Year
2010
Total Cost
$313,325
Indirect Cost
Name
Pennsylvania State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Gowda, Raghavendra; Dinavahi, Saketh S; Iyer, Soumya et al. (2018) Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment. Nanomedicine 14:863-873
Dinavahi, Saketh S; Noory, Mohammad A; Gowda, Raghavendra et al. (2018) Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations. Mol Pharmacol 93:190-196
Gowda, Raghavendra; Sharma, Arati; Robertson, Gavin P (2017) Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. Cancer Lett 385:243-250
Kuzu, Omer F; Gowda, Raghavendra; Noory, Mohammad A et al. (2017) Modulating cancer cell survival by targeting intracellular cholesterol transport. Br J Cancer 117:513-524
Gowda, Raghavendra; Kardos, Gregory; Sharma, Arati et al. (2017) Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. Mol Cancer Ther 16:440-452
Gowda, Raghavendra; Inamdar, Gajanan S; Kuzu, Omer et al. (2017) Identifying the structure-activity relationship of leelamine necessary for inhibiting intracellular cholesterol transport. Oncotarget 8:28260-28277
Kuzu, Omer F; Noory, Mohammad A; Robertson, Gavin P (2016) The Role of Cholesterol in Cancer. Cancer Res 76:2063-70
Kardos, Gregory R; Wastyk, Hannah C; Robertson, Gavin P (2015) Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway. Mol Cancer Res 13:1408-20
Sadashiva, Maralinganadoddi P; Gowda, Raghavendra; Wu, Xianzhu et al. (2015) A non-cytotoxic N-dehydroabietylamine derivative with potent antimalarial activity. Exp Parasitol 155:68-73
Kardos, Gregory R; Robertson, Gavin P (2015) Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell Melanoma Res 28:501-19

Showing the most recent 10 out of 39 publications